Dianthus Therapeutics (DNTH) Change in Account Payables (2017 - 2025)

Dianthus Therapeutics' Change in Account Payables history runs 9 years deep, the most recent figure standing at $3.0 million for Q3 2025.

• On a quarterly basis, Change in Account Payables fell 46.84% year-over-year to $3.0 million in Q3 2025; TTM through Sep 2025 was $6.9 million, a 8.53% decrease from a year earlier, with the FY2024 full-year figure at $8.2 million, up 1139.18% from the prior year.
• Change in Account Payables slipped to $3.0 million in Q3 2025 per DNTH's latest filing, from $3.1 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $5.7 million in Q3 2024 and bottomed at -$4.7 million in Q1 2023.
• The 5-year median for Change in Account Payables is $773000.0 (2023), against an average of $627578.9.
• Across the five-year window, Change in Account Payables tumbled 583.14% in 2022 and soared 631.05% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at $1.2 million in 2021, then sank by 129.38% to -$339000.0 in 2022, then surged by 572.86% to $1.6 million in 2023, then jumped by 42.23% to $2.3 million in 2024, then jumped by 31.75% to $3.0 million in 2025.
• Per Business Quant, the three latest DNTH Change in Account Payables figures stand at $3.0 million (Q3 2025), $3.1 million (Q2 2025), and -$1.5 million (Q1 2025).